Profile data is unavailable for this security.
About the company
J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing of medicated and herbal lozenges. All its lozenges (herbal, medicated and soft-centered) can be made in sugar and sugar-free options. It has implemented osmotic-controlled release oral drug delivery system (OROS) technology. It maintains a direct presence in Russia and South Africa, along with distributor relationships in the United States and various markets throughout Asia, Africa, and Latin America.
- Revenue in INR (TTM)35.92bn
- Net income in INR5.87bn
- Incorporated1976
- Employees5.31k
- LocationJ B Chemicals and Pharmaceuticals LtdCnergy It Park, Appa Saheb Marathe MargMUMBAI 400025IndiaIND
- Phone+91 2 224395200
- Fax+91 2 224395500
- Websitehttps://jbpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wockhardt Ltd | 28.93bn | -3.43bn | 185.39bn | 2.39k | -- | -- | -- | 6.41 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 187.40bn | 1.65k | 55.76 | -- | 47.03 | 11.46 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 190.62bn | 940.00 | 198.86 | -- | 171.87 | 13.74 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Concord Biotech Ltd | 10.38bn | 3.13bn | 191.48bn | 1.38k | 61.15 | -- | 52.18 | 18.45 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Jubilant Pharmova Ltd | 69.20bn | 5.93bn | 191.94bn | 995.00 | 32.41 | 3.23 | 19.86 | 2.77 | 37.38 | 37.38 | 436.41 | 375.04 | 0.5934 | 1.75 | 8.15 | 69,544,720.00 | 5.05 | 2.96 | 6.01 | 3.55 | 68.50 | 68.47 | 8.51 | 5.13 | 1.20 | 2.51 | 0.342 | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 221.89bn | 14.86k | 35.23 | -- | 24.51 | 3.52 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
Pfizer Ltd | 22.38bn | 6.18bn | 233.22bn | 1.72k | 37.75 | 6.22 | 34.36 | 10.42 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Natco Pharma Ltd. | 42.21bn | 16.37bn | 251.28bn | 4.02k | 15.35 | -- | 13.78 | 5.95 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Laurus Labs Ltd | 50.53bn | 1.31bn | 264.86bn | 6.01k | 201.92 | 6.40 | 48.58 | 5.24 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
Gland Pharma Ltd | 58.58bn | 7.22bn | 272.02bn | 4.22k | 37.67 | -- | 24.88 | 4.64 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 272.13bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 304.58bn | 5.31k | 53.02 | -- | 41.45 | 8.48 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 334.35bn | 1.05k | 138.89 | -- | 112.99 | 35.78 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Piramal Pharma Ltd | 87.04bn | 453.30m | 354.33bn | 6.72k | 787.95 | 4.48 | 44.04 | 4.07 | 0.3407 | 0.3407 | 66.36 | 59.91 | 0.5799 | 1.40 | 4.88 | 12,954,040.00 | 0.302 | -- | 0.428 | -- | 63.69 | -- | 0.5208 | -- | 0.5603 | 7.49 | 0.3771 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Ajanta Pharma Ltd | 44.91bn | 8.75bn | 382.82bn | 7.84k | 44.06 | 10.41 | 37.83 | 8.52 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
IPCA Laboratories Ltd | 82.12bn | 5.77bn | 403.09bn | 17.34k | 69.88 | -- | 42.48 | 4.91 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
Holder | Shares | % Held |
---|---|---|
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Sep 2024 | 4.67m | 3.01% |
Axis Asset Management Co. Ltd.as of 30 Sep 2024 | 4.37m | 2.81% |
Abrdn Asia Ltd.as of 24 Oct 2024 | 3.78m | 2.44% |
The Vanguard Group, Inc.as of 02 Oct 2024 | 2.61m | 1.68% |
Kotak Mahindra Asset Management Co. Ltd.as of 30 Sep 2024 | 2.60m | 1.68% |
Norges Bank Investment Managementas of 30 Sep 2024 | 2.47m | 1.59% |
Canara Robeco Asset Management Co. Ltd.as of 30 Sep 2024 | 1.96m | 1.26% |
Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 1.86m | 1.20% |
Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 1.45m | 0.93% |
Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 1.38m | 0.89% |